An Investment in Generics Turns Heads
This article was originally published in Start Up
Executive Summary
Galen Associates' $20 million investment in the troubled Halsey Drugs generics company is turning heads. Not only is it a huge amount of money for a venture firm, but generics has never been an industry which attracts venture capital. But Galen and Michael Reicher, the new CEO of Halsey see ways to make money in niche generics markets, especially as the industry climbs out of a long slump